according to the Globally Harmonized System



# **Orbifloxacin Liquid Formulation**

Revision Date: Date of last issue: 04.04.2023 Version SDS Number: 4.0 30.09.2023 785872-00016 Date of first issue: 28.06.2016

#### 1. PRODUCT AND COMPANY IDENTIFICATION

Product name Orbifloxacin Liquid Formulation

Manufacturer or supplier's details

Company : MSD

Address Briahnager - Off Pune Nagar Road

Wagholi - Pune - India 412 207

Telephone +1-908-740-4000

Emergency telephone number: +1-908-423-6000

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Veterinary product Recommended use Restrictions on use Not applicable

### 2. HAZARDS IDENTIFICATION

#### Manufacture, Storage and Import of Hazardous Chemicals Rules 1989

#### Classification

Not classified as hazardous according to criteria laid down in Part I of Schedule-1.

**GHS Classification** 

Reproductive toxicity Category 2

Specific target organ toxicity - :

repeated exposure (Oral)

Category 2 (Eye)

**GHS** label elements

Hazard pictograms

Signal word

Hazard statements H361d Suspected of damaging the unborn child.

H373 May cause damage to organs (Eye) through prolonged or

repeated exposure if swallowed.

Precautionary statements Prevention:

P203 Obtain, read and follow all safety instructions before use.

according to the Globally Harmonized System



# **Orbifloxacin Liquid Formulation**

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 4.0 30.09.2023 785872-00016 Date of first issue: 28.06.2016

P260 Do not breathe mist or vapours.

P280 Wear protective gloves/ protective clothing/ eye protec-

tion/ face protection.

Response:

P318 IF exposed or concerned, get medical advice.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste

disposal plant.

#### Other hazards which do not result in classification

None known.

#### 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

#### Components

Chemical name	CAS-No.	Concentration (% w/w)
Orbifloxacin	113617-63-3	>= 3 - < 5
Silicon dioxide	7631-86-9	>= 1 - < 5
Lactic acid	50-21-5	>= 1 - < 3
Sodium hydroxide	1310-73-2	>= 1 - < 2

#### 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled : If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty

of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse. Flush eyes with water as a precaution.

Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and

In case of eye contact

Suspected of damaging the unborn child.

and effects, both acute and delayed

May cause damage to organs through prolonged or repeated

exposure if swallowed.

Protection of first-aiders : First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment

according to the Globally Harmonized System



# **Orbifloxacin Liquid Formulation**

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 4.0 30.09.2023 785872-00016 Date of first issue: 28.06.2016

when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical None known.

Unsuitable extinguishing

media

Specific hazards during fire-

fighting

Hazardous combustion prod-

ucts

Exposure to combustion products may be a hazard to health.

Carbon oxides Metal oxides

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Special protective equipment :

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

#### 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protec- :

tive equipment and emer-

gency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so.

Prevent spreading over a wide area (e.g. by containment or oil

barriers).

Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up

Soak up with inert absorbent material.

For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absor-

bent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

#### 7. HANDLING AND STORAGE

according to the Globally Harmonized System



## **Orbifloxacin Liquid Formulation**

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 30.09.2023 785872-00016 Date of first issue: 28.06.2016 4.0

Technical measures See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation Use only with adequate ventilation. Advice on safe handling Do not breathe mist or vapours.

Do not swallow.

Avoid contact with eyes.

Avoid prolonged or repeated contact with skin.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

Take care to prevent spills, waste and minimize release to the

environment.

Conditions for safe storage Keep in properly labelled containers.

Store locked up.

Store in accordance with the particular national regulations.

Do not store with the following product types: Materials to avoid

Strong oxidizing agents

#### 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

#### Components with workplace control parameters

Components	CAS-No.	Value type	Control parame-	Basis
		(Form of	ters / Permissible	
		exposure)	concentration	
Orbifloxacin	113617-63-3	TWA	0.2 mg/m3 (OEB	Internal
			2)	
Silicon dioxide	7631-86-9	TWA (Total	10 mg/m3	IN OEL
		dust)	(Silica)	
Sodium hydroxide	1310-73-2	CEIL	2 mg/m3	IN OEL
		С	2 mg/m3	ACGIH

**Engineering measures** Use appropriate engineering controls and manufacturing

technologies to control airborne concentrations (e.g., drip-less

quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to

protect products, workers, and the environment.

Laboratory operations do not require special containment.

Personal protective equipment

Respiratory protection If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection. Combined particulates and organic vapour type

Filter type Hand protection Material

Chemical-resistant gloves

Eye protection

Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

according to the Globally Harmonized System



# **Orbifloxacin Liquid Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 4.0
 30.09.2023
 785872-00016
 Date of first issue: 28.06.2016

aerosols.

Skin and body protection : Work uniform or laboratory coat.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working

place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

### 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : suspension

Colour : light brown

Odour : odourless

Odour Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flash point : No data available

Evaporation rate : No data available

Flammability (solid, gas) : Not applicable

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapour pressure : No data available

Relative vapour density : No data available

Relative density : No data available

Density : No data available

Solubility(ies)

Water solubility : No data available

according to the Globally Harmonized System



# **Orbifloxacin Liquid Formulation**

**Revision Date:** Version SDS Number: Date of last issue: 04.04.2023 4.0 30.09.2023 785872-00016 Date of first issue: 28.06.2016

Partition coefficient: n-

octanol/water

No data available

Auto-ignition temperature No data available

Decomposition temperature No data available

Viscosity

No data available Viscosity, kinematic

Explosive properties Not explosive

Oxidizing properties The substance or mixture is not classified as oxidizing.

Molecular weight No data available

Particle size No data available

#### 10. STABILITY AND REACTIVITY

Reactivity Not classified as a reactivity hazard. Chemical stability Stable under normal conditions. Can react with strong oxidizing agents.

Possibility of hazardous reac-

tions

Conditions to avoid None known. Incompatible materials Oxidizing agents

Hazardous decomposition

products

No hazardous decomposition products are known.

#### 11. TOXICOLOGICAL INFORMATION

Information on likely routes of:

exposure

Inhalation Skin contact

> Ingestion Eye contact

**Acute toxicity** 

Not classified based on available information.

**Product:** 

Acute toxicity estimate: > 5,000 mg/kg Acute oral toxicity

Method: Calculation method

Acute inhalation toxicity Acute toxicity estimate: > 10 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist Method: Calculation method

Components:

Orbifloxacin:

Acute oral toxicity LD50 (Rat): > 3,000 mg/kg

according to the Globally Harmonized System



# **Orbifloxacin Liquid Formulation**

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 4.0 30.09.2023 785872-00016 Date of first issue: 28.06.2016

Remarks: No mortality observed at this dose.

LD50 (Mouse): > 2,000 mg/kg

Remarks: No mortality observed at this dose.

LD50 (Dog): > 600 mg/kg Symptoms: Vomiting

Remarks: No mortality observed at this dose.

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

Acute toxicity (other routes of :

administration)

LD50 (Rat): > 200 mg/kg

Application Route: Intramuscular

LD50 (Mouse): 500 mg/kg Application Route: Intramuscular

LD50 (Rat): 233 mg/kg

Application Route: Intravenous

LD50 (Mouse): 250 mg/kg Application Route: Intravenous

Silicon dioxide:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Method: OECD Test Guideline 401

Acute inhalation toxicity : LC50 (Rat): > 2.08 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Assessment: The substance or mixture has no acute inhala-

tion toxicity

Acute dermal toxicity : LD50 (Rabbit): > 5,000 mg/kg

Lactic acid:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg

Remarks: Based on data from similar materials

Acute inhalation toxicity : LC50 (Rat): > 5 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Method: OECD Test Guideline 403

Assessment: Corrosive to the respiratory tract. Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Assessment: The substance or mixture has no acute dermal

toxicity

Remarks: Based on data from similar materials

according to the Globally Harmonized System



## **Orbifloxacin Liquid Formulation**

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 4.0 30.09.2023 785872-00016 Date of first issue: 28.06.2016

Sodium hydroxide:

Acute inhalation toxicity : Assessment: Corrosive to the respiratory tract.

Skin corrosion/irritation

Not classified based on available information.

**Product:** 

Species : Rabbit

Result : No skin irritation

Components:

Orbifloxacin:

Species : Rabbit
Method : Draize Test
Result : No skin irritation

Silicon dioxide:

Species : Rabbit

Method : OECD Test Guideline 404

Result : No skin irritation

Lactic acid:

Species : Rabbit

Method : OECD Test Guideline 404

Result : Corrosive after 1 to 4 hours of exposure Remarks : Based on data from similar materials

Sodium hydroxide:

Result : Corrosive after 3 minutes or less of exposure

Serious eye damage/eye irritation

Not classified based on available information.

**Product:** 

Species : Rabbit

Result : Mild eye irritation

**Components:** 

Orbifloxacin:

Species : Rabbit
Method : Draize Test
Result : Mild eye irritation

Silicon dioxide:

Species : Rabbit

Method : OECD Test Guideline 405

Result : No eye irritation

according to the Globally Harmonized System



# **Orbifloxacin Liquid Formulation**

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 4.0 30.09.2023 785872-00016 Date of first issue: 28.06.2016

Lactic acid:

Species : Chicken eye

Remarks : Based on data from similar materials

Result : Irreversible effects on the eye

**Sodium hydroxide:** 

Result : Irreversible effects on the eye Remarks : Based on skin corrosivity.

#### Respiratory or skin sensitisation

#### Skin sensitisation

Not classified based on available information.

#### Respiratory sensitisation

Not classified based on available information.

**Product:** 

Test Type : Magnusson-Kligman-Test

Exposure routes : Dermal Species : Guinea pig

Result : Not a skin sensitizer.

#### **Components:**

#### Orbifloxacin:

Test Type : Maximisation Test

Exposure routes : Dermal Species : Guinea pig

Result : Not a skin sensitizer.

Lactic acid:

Test Type : Buehler Test
Exposure routes : Skin contact
Species : Guinea pig
Result : negative

Remarks : Based on data from similar materials

Sodium hydroxide:

Test Type : Human repeat insult patch test (HRIPT)

Exposure routes : Skin contact
Result : negative

### Germ cell mutagenicity

Not classified based on available information.

according to the Globally Harmonized System



# **Orbifloxacin Liquid Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 4.0
 30.09.2023
 785872-00016
 Date of first issue: 28.06.2016

#### **Components:**

#### Orbifloxacin:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: equivocal

Test Type: Mouse Lymphoma

Result: positive

Test Type: Chromosomal aberration Test system: Human lymphocytes

Result: positive

Genotoxicity in vivo : Test Type: Micronucleus test

Species: Mouse

Cell type: Bone marrow

Application Route: Intraperitoneal injection

Result: negative

Test Type: unscheduled DNA synthesis assay

Species: Rat

Cell type: Liver cells Application Route: Oral

Result: negative

Germ cell mutagenicity -

Assessment

Weight of evidence does not support classification as a germ

cell mutagen.

#### Silicon dioxide:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Method: OECD Test Guideline 471

Result: negative

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow

cytogenetic test, chromosomal analysis)

Species: Rat

Application Route: Ingestion

Result: negative

### Lactic acid:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Method: OECD Test Guideline 471

Result: negative

Remarks: Based on data from similar materials

Test Type: In vitro mammalian cell gene mutation test

Method: OECD Test Guideline 476

Result: negative

Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro

Method: OECD Test Guideline 473

Result: negative

according to the Globally Harmonized System



# **Orbifloxacin Liquid Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 4.0
 30.09.2023
 785872-00016
 Date of first issue: 28.06.2016

Remarks: Based on data from similar materials

### Carcinogenicity

Not classified based on available information.

#### **Components:**

#### Orbifloxacin:

Species : Rat
Application Route : Oral
Exposure time : 2 Years

NOAEL : 200 mg/kg body weight

Result : negative

Species : Mouse
Application Route : Oral
Exposure time : 2 Years

NOAEL : 200 mg/kg body weight

Result : negative

#### Silicon dioxide:

Species : Rat
Application Route : Ingestion
Exposure time : 103 weeks
Result : negative

#### Lactic acid:

Species : Rat
Application Route : Ingestion
Exposure time : 2 Years
Result : negative

Remarks : Based on data from similar materials

#### Reproductive toxicity

Suspected of damaging the unborn child.

#### **Components:**

#### Orbifloxacin:

Effects on fertility : Test Type: Two-generation reproduction toxicity study

Species: Rat

Application Route: Oral

General Toxicity - Parent: NOAEL: 50 mg/kg body weight Early Embryonic Development: NOAEL: 50 mg/kg body

weight

Result: No adverse effects

Test Type: Embryo-foetal development

Effects on foetal develop-

ment Species: Rat

Application Route: Oral

Embryo-foetal toxicity: LOAEL: 333 mg/kg body weight

according to the Globally Harmonized System



# **Orbifloxacin Liquid Formulation**

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 4.0 30.09.2023 785872-00016 Date of first issue: 28.06.2016

Result: No teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high ma-

ternally toxic doses

Test Type: Embryo-foetal development

Species: Rabbit Application Route: Oral

General Toxicity Maternal: NOAEL: 20 mg/kg body weight Embryo-foetal toxicity: NOAEL: 60 mg/kg body weight Result: No effects on early embryonic development, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses, Reduced maternal

body weight gain

Test Type: Development

Species: Dog

Application Route: Oral

Developmental Toxicity: LOAEL: 2.5 mg/kg body weight Result: Effects on postnatal development, Skeletal malfor-

mations

Reproductive toxicity - As-

sessment

Some evidence of adverse effects on development, based on

animal experiments.

### Silicon dioxide:

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rat

Application Route: Ingestion

Result: negative

### Lactic acid:

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Mouse

Application Route: Ingestion

Result: negative

#### STOT - single exposure

Not classified based on available information.

#### STOT - repeated exposure

May cause damage to organs (Eye) through prolonged or repeated exposure if swallowed.

#### **Product:**

Target Organs : Eye

Assessment : May cause damage to organs through prolonged or repeated

exposure.

### Repeated dose toxicity

#### **Product:**

Species : Dog NOAEL : 22.5 mg/kg

according to the Globally Harmonized System



# **Orbifloxacin Liquid Formulation**

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 4.0 30.09.2023 785872-00016 Date of first issue: 28.06.2016

LOAEL : 37.5 mg/kg
Application Route : Oral
Exposure time : 30 Days

Symptoms : Gastrointestinal disturbance

Species : Dog LOAEL : 75 mg/kg Application Route : Oral Exposure time : 10 Days

Symptoms : Salivation, Gastrointestinal disturbance, Vomiting

Species : Cat
LOAEL : 45 mg/kg
Application Route : Oral
Exposure time : 30 Days
Target Organs : Eye

Symptoms : Salivation, Lachrymation, Gastrointestinal disturbance, Liver

disorders

#### **Components:**

#### Orbifloxacin:

Species : Rat

NOAEL : 20 mg/kg

LOAEL : 80 mg/kg

Application Route : Oral

Exposure time : 3 Months

Target Organs : Testis, Liver, Kidney, spleen

Species : Mouse

NOAEL : 80 mg/kg

LOAEL : 250 mg/kg

Application Route : Oral

Exposure time : 3 Months

Species : Juvenile dog
NOAEL : 50 mg/kg
LOAEL : 250 mg/kg
Application Route : Oral
Exposure time : 14 Days
Target Organs : Heart, Bone

Symptoms : Gastrointestinal disturbance

Remarks : mortality observed

Species : Juvenile dog
NOAEL : 2 mg/kg
LOAEL : 3 mg/kg
Application Route : Oral
Exposure time : 90 Days
Target Organs : Bone

Remarks : No significant adverse effects were reported

Species : Dog NOAEL : 37.5 mg/kg

according to the Globally Harmonized System



## **Orbifloxacin Liquid Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 4.0
 30.09.2023
 785872-00016
 Date of first issue: 28.06.2016

Application Route : Oral Exposure time : 30 Days

Species : Cat

 NOAEL
 : 7.5 mg/kg

 LOAEL
 : 22.5 mg/kg

Application Route : Oral Exposure time : 1 Months

Symptoms : Gastrointestinal disturbance

Silicon dioxide:

Species : Rat

NOAEL : 1.3 mg/m3

Application Route : inhalation (dust/mist/fume)

Exposure time : 13 Weeks

Lactic acid:

Species : Rat

NOAEL : > 100 mg/kg
Application Route : Ingestion
Exposure time : 13 Weeks

Remarks : Based on data from similar materials

Species : Rat

LOAEL : 886 mg/kg
Application Route : Skin contact
Exposure time : 13 Weeks

**Aspiration toxicity** 

Not classified based on available information.

**Experience with human exposure** 

**Components:** 

Orbifloxacin:

Ingestion : Symptoms: central nervous system effects, Gastrointestinal

disturbance, liver function change, anaphylaxis, Rash

Remarks: May cause photosensitisation.

#### 12. ECOLOGICAL INFORMATION

**Ecotoxicity** 

Components:

Silicon dioxide:

Toxicity to fish : LC50 (Danio rerio (zebra fish)): > 10,000 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

Toxicity to daphnia and other : EC50 (Daphnia magna (Water flea)): > 1,000 mg/l

according to the Globally Harmonized System



## **Orbifloxacin Liquid Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 4.0
 30.09.2023
 785872-00016
 Date of first issue: 28.06.2016

aquatic invertebrates Exposure time: 24 h

Method: OECD Test Guideline 202

Toxicity to algae/aquatic

plants

EC50 ( Desmodesmus subspicatus (green algae)): > 10,000 mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: Based on data from similar materials

NOEC (Desmodesmus subspicatus (green algae)): 10,000

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: Based on data from similar materials

Lactic acid:

Toxicity to fish : LC50 (Danio rerio (zebra fish)): > 100 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

Remarks: Based on data from similar materials

Toxicity to daphnia and other:

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 100 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Remarks: Based on data from similar materials

Toxicity to algae/aquatic

plants

ErC50 (Pseudokirchneriella subcapitata (green algae)): > 100

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: Based on data from similar materials

NOEC (Pseudokirchneriella subcapitata (green algae)): > 100

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: Based on data from similar materials

Toxicity to microorganisms : EC50: > 10 - 100 mg/l

Exposure time: 3 h

Method: OECD Test Guideline 209

Remarks: Based on data from similar materials

Persistence and degradability

**Components:** 

Lactic acid:

Biodegradability : Result: Not readily biodegradable.

Remarks: Based on data from similar materials

according to the Globally Harmonized System



## **Orbifloxacin Liquid Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 4.0
 30.09.2023
 785872-00016
 Date of first issue: 28.06.2016

#### Bioaccumulative potential

#### **Components:**

Lactic acid:

Partition coefficient: n-

octanol/water

: log Pow: -0.62

### Mobility in soil

No data available

#### Other adverse effects

No data available

#### 13. DISPOSAL CONSIDERATIONS

#### Disposal methods

Waste from residues : Do not dispose of waste into sewer.

Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

#### 14. TRANSPORT INFORMATION

#### International Regulations

#### **UNRTDG**

Not regulated as a dangerous good

#### **IATA-DGR**

Not regulated as a dangerous good

## **IMDG-Code**

Not regulated as a dangerous good

#### Transport in bulk according to IMO instruments

Not applicable for product as supplied.

#### Special precautions for user

Not applicable

#### 15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mix-

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

according to the Globally Harmonized System



# **Orbifloxacin Liquid Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 4.0
 30.09.2023
 785872-00016
 Date of first issue: 28.06.2016

#### **16. OTHER INFORMATION**

Revision Date : 30.09.2023

**Further information** 

Sources of key data used to

compile the Safety Data

Sheet

: Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Date format : dd.mm.yyyy

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

IN OEL : India. Permissible levels of certain chemical substances in

work environment.

ACGIH / C : Ceiling limit

IN OEL / TWA : Time-Weighted Average Concentration (TWA) (8 hrs.)

IN OEL / CEIL : ceiling limit

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk, IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals: OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods: vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

according to the Globally Harmonized System



# **Orbifloxacin Liquid Formulation**

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 4.0 30.09.2023 785872-00016 Date of first issue: 28.06.2016

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IN / EN